Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 5.23
CYTK's Cash-to-Debt is ranked lower than
62% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. CYTK: 5.23 )
Ranked among companies with meaningful Cash-to-Debt only.
CYTK' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.83  Med: 10.11 Max: No Debt
Current: 5.23
Equity-to-Asset 0.56
CYTK's Equity-to-Asset is ranked lower than
60% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CYTK: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
CYTK' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.46  Med: 0.65 Max: 0.91
Current: 0.56
-1.46
0.91
Interest Coverage 7.39
CYTK's Interest Coverage is ranked lower than
87% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTK: 7.39 )
Ranked among companies with meaningful Interest Coverage only.
CYTK' s Interest Coverage Range Over the Past 10 Years
Min: 6.93  Med: 5031.9 Max: No Debt
Current: 7.39
Piotroski F-Score: 6
Altman Z-Score: 1.71
Beneish M-Score: 4.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 17.56
CYTK's Operating Margin % is ranked higher than
86% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. CYTK: 17.56 )
Ranked among companies with meaningful Operating Margin % only.
CYTK' s Operating Margin % Range Over the Past 10 Years
Min: -1926.08  Med: -272.6 Max: 32
Current: 17.56
-1926.08
32
Net Margin % 15.46
CYTK's Net Margin % is ranked higher than
86% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. CYTK: 15.46 )
Ranked among companies with meaningful Net Margin % only.
CYTK' s Net Margin % Range Over the Past 10 Years
Min: -1912.57  Med: -244.9 Max: 30.1
Current: 15.46
-1912.57
30.1
ROE % 23.31
CYTK's ROE % is ranked higher than
94% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. CYTK: 23.31 )
Ranked among companies with meaningful ROE % only.
CYTK' s ROE % Range Over the Past 10 Years
Min: -85.46  Med: -50.79 Max: 32.47
Current: 23.31
-85.46
32.47
ROA % 12.41
CYTK's ROA % is ranked higher than
92% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. CYTK: 12.41 )
Ranked among companies with meaningful ROA % only.
CYTK' s ROA % Range Over the Past 10 Years
Min: -73.2  Med: -36.09 Max: 23.37
Current: 12.41
-73.2
23.37
ROC (Joel Greenblatt) % 185.73
CYTK's ROC (Joel Greenblatt) % is ranked higher than
96% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. CYTK: 185.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CYTK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3507.33  Med: -583.53 Max: 710.88
Current: 185.73
-3507.33
710.88
3-Year Revenue Growth Rate 30.50
CYTK's 3-Year Revenue Growth Rate is ranked higher than
79% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CYTK: 30.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CYTK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -32.1 Max: 154.5
Current: 30.5
0
154.5
GuruFocus has detected 3 Warning Signs with Cytokinetics Inc $CYTK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CYTK's 10-Y Financials

Financials (Next Earnings Date: 2017-05-16 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CYTK Guru Trades in Q1 2016

Charles Brandes Sold Out
Paul Tudor Jones 15,008 sh (-45.76%)
Jim Simons 184,479 sh (-64.47%)
» More
Q2 2016

CYTK Guru Trades in Q2 2016

Paul Tudor Jones 16,470 sh (+9.74%)
Jim Simons Sold Out
» More
Q3 2016

CYTK Guru Trades in Q3 2016

Paul Tudor Jones 41,300 sh (+150.76%)
» More
Q4 2016

CYTK Guru Trades in Q4 2016

Paul Tudor Jones 17,240 sh (-58.26%)
» More
» Details

Insider Trades

Latest Guru Trades with CYTK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:NTLA, NAS:SPPI, NAS:IMMU, NAS:ANIP, NAS:ESPR, NAS:ANAB, NAS:RARX, NAS:ENTA, NAS:ACHN, NAS:MCRB, NAS:CTMX, NAS:CRBP, NAS:XBIT, NAS:MRUS, OTCPK:SPHDF, NAS:INO, NAS:MYOK, NAS:OMER, NAS:ATRA, NAS:NLNK » details
Traded in other countries:KK3A.Germany,
Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.

Cytokinetics is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatment for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility.

Ratios

vs
industry
vs
history
PE Ratio 37.76
CYTK's PE Ratio is ranked lower than
57% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. CYTK: 37.76 )
Ranked among companies with meaningful PE Ratio only.
CYTK' s PE Ratio Range Over the Past 10 Years
Min: 6.6  Med: 10.46 Max: 38.24
Current: 37.76
6.6
38.24
PE Ratio without NRI 37.76
CYTK's PE Ratio without NRI is ranked lower than
59% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. CYTK: 37.76 )
Ranked among companies with meaningful PE Ratio without NRI only.
CYTK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 6.6  Med: 10.46 Max: 38.24
Current: 37.76
6.6
38.24
Price-to-Owner-Earnings 19.13
CYTK's Price-to-Owner-Earnings is ranked higher than
63% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 26.25 vs. CYTK: 19.13 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CYTK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 15.18  Med: 84.34 Max: 222.59
Current: 19.13
15.18
222.59
PB Ratio 5.49
CYTK's PB Ratio is ranked lower than
65% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CYTK: 5.49 )
Ranked among companies with meaningful PB Ratio only.
CYTK' s PB Ratio Range Over the Past 10 Years
Min: 0.89  Med: 2.33 Max: 9.96
Current: 5.49
0.89
9.96
PS Ratio 5.13
CYTK's PS Ratio is ranked higher than
71% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. CYTK: 5.13 )
Ranked among companies with meaningful PS Ratio only.
CYTK' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 12.1 Max: 95.5
Current: 5.13
1.84
95.5
Price-to-Free-Cash-Flow 16.38
CYTK's Price-to-Free-Cash-Flow is ranked higher than
64% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 22.69 vs. CYTK: 16.38 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CYTK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.99  Med: 44.76 Max: 100.26
Current: 16.38
12.99
100.26
Price-to-Operating-Cash-Flow 15.59
CYTK's Price-to-Operating-Cash-Flow is ranked higher than
62% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 23.59 vs. CYTK: 15.59 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CYTK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 39.63 Max: 89.3
Current: 15.59
12.38
89.3
EV-to-EBIT 21.59
CYTK's EV-to-EBIT is ranked lower than
54% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. CYTK: 21.59 )
Ranked among companies with meaningful EV-to-EBIT only.
CYTK' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.6  Med: -1.8 Max: 227.5
Current: 21.59
-18.6
227.5
EV-to-EBITDA 20.80
CYTK's EV-to-EBITDA is ranked lower than
58% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. CYTK: 20.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
CYTK' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.1  Med: -1.8 Max: 173.6
Current: 20.8
-19.1
173.6
Current Ratio 4.77
CYTK's Current Ratio is ranked higher than
57% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. CYTK: 4.77 )
Ranked among companies with meaningful Current Ratio only.
CYTK' s Current Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.5 Max: 11.14
Current: 4.77
2.58
11.14
Quick Ratio 4.77
CYTK's Quick Ratio is ranked higher than
58% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CYTK: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
CYTK' s Quick Ratio Range Over the Past 10 Years
Min: 2.58  Med: 5.5 Max: 11.14
Current: 4.77
2.58
11.14
Days Sales Outstanding 0.08
CYTK's Days Sales Outstanding is ranked higher than
100% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. CYTK: 0.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
CYTK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.06  Med: 1.05 Max: 362.71
Current: 0.08
0.06
362.71

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -9.70
CYTK's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CYTK: -9.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CYTK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -182.7  Med: -22.85 Max: -9.7
Current: -9.7
-182.7
-9.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.46
CYTK's Price-to-Net-Cash is ranked higher than
51% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. CYTK: 6.46 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CYTK' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.41  Med: 3.62 Max: 7.35
Current: 6.46
1.41
7.35
Price-to-Net-Current-Asset-Value 6.30
CYTK's Price-to-Net-Current-Asset-Value is ranked lower than
52% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. CYTK: 6.30 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CYTK' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.37  Med: 3.44 Max: 6.63
Current: 6.3
1.37
6.63
Price-to-Tangible-Book 5.52
CYTK's Price-to-Tangible-Book is ranked lower than
58% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. CYTK: 5.52 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CYTK' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.34  Med: 2.71 Max: 6.04
Current: 5.52
1.34
6.04
Price-to-Median-PS-Value 0.42
CYTK's Price-to-Median-PS-Value is ranked higher than
86% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. CYTK: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CYTK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.17  Med: 0.94 Max: 7.01
Current: 0.42
0.17
7.01
Price-to-Graham-Number 3.05
CYTK's Price-to-Graham-Number is ranked lower than
55% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.54 vs. CYTK: 3.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CYTK' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.74  Med: 1.72 Max: 3.06
Current: 3.05
0.74
3.06
Earnings Yield (Greenblatt) % 4.68
CYTK's Earnings Yield (Greenblatt) % is ranked higher than
88% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. CYTK: 4.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CYTK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 29 Max: 3342.8
Current: 4.68
0.4
3342.8

More Statistics

Revenue (TTM) (Mil) $106.4
EPS (TTM) $ 0.34
Beta2.35
Short Percentage of Float6.81%
52-Week Range $6.27 - 13.70
Shares Outstanding (Mil)41.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22 40 70
EPS ($) -3.23 -2.53 -2.19
EPS without NRI ($) -3.23 -2.53 -2.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CYTK

Headlines

Articles On GuruFocus.com
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Aug 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares Jun 04 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 25,000 Shares May 20 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares May 14 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) May 07 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 28 2010 
Cytokinetics Inc. (CYTK) Former Executive Chairman James H Sabry sells 10,000 Shares Apr 01 2010 
Cytokinetics Inc. Reports Operating Results (10-Q) Nov 05 2009 
Cytokinetics Inc. (CYTK) President & CEO Robert I Blum sells 1,000 Shares Aug 06 2009 

More From Other Websites
CYTOKINETICS INC Files SEC form 8-K, Other Events Mar 23 2017
7:34 am Cytokinetics and Origent Data Sciences announce the advancement of their research... Mar 23 2017
Origent Data Sciences and Cytokinetics Advance Collaboration Intended to Validate Predictive... Mar 23 2017
Cytokinetics SMA Drug Did Well in Early Study Mar 22 2017
Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference Mar 22 2017
CYTOKINETICS INC Files SEC form 8-K, Other Events Mar 20 2017
Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17 Mar 20 2017
Key Indexes Rise, Steel Stocks Up Before Fed News; A Curious Trend In IBD 50 Mar 15 2017
CYTOKINETICS INC Financials Mar 10 2017
Biotech Firm's Stock Options Complicate Its Valuation Mar 10 2017
7 Stocks Trending Up With Monster Volume Mar 09 2017
Coverage initiated on Cytokinetics by Rodman & Renshaw Mar 08 2017
CYTOKINETICS INC Files SEC form 10-K, Annual Report Mar 06 2017
Cytokinetics Announces Presentation of Additional Results from COSMIC-HF at ACC.17 Mar 06 2017
Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : March 6, 2017 Mar 06 2017
CYTOKINETICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Mar 02 2017
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day Feb 28 2017
Cytokinetics to Present at March Investor Conferences Feb 27 2017
Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017 Feb 23 2017
Cytokinetics, Inc. :CYTK-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017 Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)